Jean Ung, MD
Urology · Winfield, ILNPI 1316908312
Payments from drug & device makers
Across 387 payments — averaging $44.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- KARL Storz Endoscopy-america$8K
- Astellas Pharma US Inc$2K
- Sumitomo Pharma America, Inc.$1K
- Axonics, Inc.$862
- AbbVie$850
- Urovant Sciences Inc$480
- plus $4K from 32 others
What the payments were for
- Consulting fees$6,35437%
- Travel & lodging$9726%
- Food & beverage$9,39755%
- Education$4503%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| KARL Storz Endoscopy-america | 12 | $7,852 |
| Astellas Pharma US Inc | 57 | $1,524 |
| Sumitomo Pharma America, Inc. | 87 | $1,382 |
| Axonics, Inc. | 16 | $862 |
| AbbVie(2 entities) | 39 | $850 |
| Urovant Sciences Inc | 29 | $480 |
| Olympus America Inc. | 9 | $361 |
| Pfizer | 20 | $328 |
| Coloplast | 26 | $328 |
| Bayer | 12 | $311 |
| Urogen Pharma, Inc. | 5 | $231 |
| Neotract Inc. | 3 | $221 |
| Procept Biorobotics Corporation | 4 | $195 |
| Teleflex LLC | 5 | $191 |
| Boston Scientific | 4 | $179 |
| Calyxo, Inc. | 5 | $138 |
| Ferring Pharmaceuticals Inc. | 3 | $136 |
| Bluewind Medical | 1 | $134 |
| C. R. Bard, Inc. & Subsidiaries | 3 | $123 |
| Tolmar, Inc. | 5 | $111 |
| AstraZeneca | 1 | $110 |
| Endo Pharmaceuticals Inc. | 7 | $110 |
| KARL Storz Lithotripsy-america | 1 | $104 |
| 180 Medical, Inc. | 4 | $97 |
| BD | 2 | $96 |
| Myovant Sciences Inc. | 6 | $91 |
| Laborie Medical Technologies Corp. | 1 | $91 |
| Blue Earth Diagnostics | 1 | $90 |
| Progenics Pharmaceuticals, Inc. | 3 | $78 |
| Halozyme Inc | 1 | $75 |
| Endo USA, Inc. | 4 | $73 |
| Dendreon Pharmaceuticals LLC | 2 | $53 |
| Johnson & Johnson | 2 | $47 |
| Mission Pharmacal Company | 2 | $33 |
| Antares Pharma, Inc. | 2 | $32 |
| Convatec Inc. | 1 | $20 |
| Lantheus Medical Imaging, Inc. | 1 | $19 |
| Hollister Incorporated | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Flex-X / IMAGE 1 S$4,458
- Flex-X$2,868
- Bulkamid$632
- Axonics$603
- UroLift$241
- N/A$155
- iTIND System$149
- JELMYTO$140
- REVI$134
- HOPKINS$127
- GENERAL KIDNEY STONE DISEASE$125
- GEMTESA$117
- XTANDI$111
- LYNPARZA$110
- MYRBETRIQ$109
- AQUABEAM SYSTEM$107
- Modulith SLX-F2 Transportable$104
- CMOS VIDEO URETEROSCOPE, 8.5 FR. X 675MM$100
How this compares
$17,173 in reported general payments places this provider in the 85th percentile of 550 urology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 15 | $219,688 |
| MyrbetriqMirabegron | 233 | $219,628 |
| GemtesaVibegron | 218 | $217,578 |
| Mirabegron ErMirabegron | 34 | $31,625 |
| Methenamine Hippurate | 219 | $17,843 |
| Trospium Chloride | 131 | $7,860 |
| Fosfomycin Tromethamine | 23 | $6,195 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 265 | $6,046 |
| Tamsulosin Hcl | 395 | $5,969 |
| Potassium Citrate ErPotassium Citrate | 44 | $5,341 |
| Trospium Chloride ErTrospium Chloride | 37 | $4,519 |
| Solifenacin Succinate | 97 | $3,946 |
| Tolterodine Tartrate ErTolterodine Tartrate | 29 | $3,863 |
| Estradiol | 53 | $3,448 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 25 | $3,377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $1,524 | $439,316248 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $1,382 | $217,578218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 550 urology providers in Illinois.
Other urology in Winfield
- Craig SmithWinfield$281K
- Mark BrandtPark Ridge$3M
- Ashley RossChicago$2.3M
- Aaron BergerChicago Ridge$2.1M
- Joshua MeeksChicago$2M
- Courtney HollowellChicago$1.9M
- David LieberSpringfield$1.5M
- Gary SteinbergChicago$1.4M
- Brian HelfandChicago$1.2M
- Simone CrivellaroChicago$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.